News for Evotec SE (EVT.DE)

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Deutsche Bank analyst Fynn Scherzler has revised the price target for Evotec (EVO), reducing it from EUR 7 to EUR 6. Despite this adjustment, the analyst mainta

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 0.50% to 44,565.39 while ...

Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platfo

HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of Evotec SE EVO fell sharply in pre-market tradi...

The company anticipates achieving an adjusted EBITDA between EUR 30 million and EUR 50 million for the fiscal year 2025. It attributes this optimism to its stra

Evotec SE revises 2025 revenue guidance to €760-800 million, down from €840-880 million. Maintains adjusted EBITDA guidance of €30-50 million desp

Evotec SE (EVO) revises 2025 revenue guidance to €760-800 million from previous €840-880 million. Maintains adjusted EBITDA guidance at €30-50 mil

Shares of Block, Inc. XYZ rose sharply in pre-market trading ahead of the S&P 500 debut of the Jack Dorsey-founded fintech company. Block will replace Hess Cor...

Evotec SE (EVO) has updated its revenue guidance for the fiscal 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged. For the current fiscal year, the company now expects Group revenues in the range of 760-800 million euros, revised from prior guidance range of 840 - 880 million euros.

Evotec SE (NASDAQ:EVO) is among the 13 Best German Stocks to Invest in Now. The company’s shares have gained over 9% in the past month, as of the close of business on July 2, amid positive recent developments. On June 25, Evotec SE (NASDAQ:EVO) announced that it had joined the NURTuRE-AKI consortium to investigate acute kidney […]

However, on a year-to-date basis, the DAX index has gained 19.48%, comfortably outperforming its US counterparts, driven by a robust show by the country’s defense stocks, as European governments unlocked...

Evotec SE (NASDAQ:EVO) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company said it would participate in the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery through multi-omics approaches. The NURTuRE-AKI consortium aims to establish the world’s largest patient cohort database […]

According to the Centers for Medicare & Medicaid Services (CMS), the US healthcare sector accounted for approximately 17.6% of GDP in 2023.

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Wednesday. Shares of DHT Holdings, Inc. DHT fell sharply in pre-market ...

RBC Capital analyst Charles Weston has updated his price target for Evotec (EVO), increasing it from EUR 11.60 to EUR 11.90. Despite the adjustment, the analyst

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The col